Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6450-6459

  Bach, Anders ^a   Chi, Celestine N ^b   Olsen, Thomas B ^a   Pedersen, Søren W ^a   Røder, Martin U ^a   Pang, Gar F ^a   Clausen, Rasmus P ^a   Jemth, Per ^b   Strømgaard, Kristian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

N (3,4 DICHLOROPHENYL)PROPYLGLUTAMYLTHREONYLALANYLVALINE; N (3,4 DIFLUOROPHENYL)PROPYLGLUTAMYLTHREONYLALANYLVALINE; N (NAPHTHALEN 2 YL)ETHYLGLUTAMYLTHREONYLALANYLVALINE; N BENZYLGLUTAMYLTHREONYLALANYLVALINE; N BUTYLGLUTAMYLTHREONYLALANYLVALINE; N CYCLOHEXYLETHYLGLUTAMYLTHREONYLALANYLVALINE; N CYCLOHEXYLMETHYLGLUTAMYLTHREONYLALANYLVALINE; N ETHYLGLUTAMYLTHREONYLALANYLVALINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLGLUTAMYLTHREONYLALANYLVALINE; N PHENYLETHYLGLUTAMYLTHREONYLALANYLVALINE; N PHENYLPROPYLGLUTAMYLTHREONYLALANYLVALINE; N PROPYLGLUTAMYLTHREONYLALANYLVALINE; PDZ PROTEIN; PDZ1 PROTEIN; PDZ2 PROTEIN; PDZ3 PROTEIN; PEPTIDE DERIVATIVE; POSTSYNAPTIC DENSITY PROTEIN 95; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BRAIN ISCHEMIA; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MOLECULAR MODEL; MOLECULAR RECOGNITION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE HOMOLOGY;

ACETYLATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PEPTIDES; RECEPTORS, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPSES;

EID: 54549115001     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800836w     Document Type: Article

References (52)

1. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discovery 2004, 3, 301-317.
2. Ryan, D. P.; Matthews, J. M. Protein-protein interactions in human disease. Curr. Opin. Struct. Biol. 2005, 15, 441-446.
3. Juliano, R. L.; Astriab-Fisher, A.; Falke, D. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Mol. Interv. 2001, 1, 40-53.
4. Berg, T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem., Int. Ed. 2003, 42, 2462-2481.
5. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 2002, 12, 14-20.
6. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280, 1-9.
7. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450, 1001-1009.
8. Chene, P. Drugs targeting protein-protein interactions. ChemMedChem 2006, 1, 400-111.
9. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
10. Kim, E.; Sheng, M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 2004, 5, 771-781.
11. Sheng, M.; Sala, C. PDZ domains and the organization of supramolecular complexes. Annu. Rev. Neurosci. 2001, 24, 1-29.
12. Schultz, J.; Copley, R. R.; Doerks, T.; Ponting, C. P.; Bork, P. SMART: a web-based tool for the study of genetically mobile domains. Nucleic Acids Res. 2000, 28, 231-234.
13. Kornau, H. C.; Schenker, L. T.; Kennedy, M. B.; Seeburg, P. H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995, 269, 1737-1740.
14. + channels by interaction with a family of membrane-associated guanylate kinases. Nature 1995, 378, 85-88.
15. Songyang, Z.; Fanning, A. S.; Fu, C.; Xu, J.; Marfatia, S. M.; Chishti, A. H.; Crompton, A.; Chan, A. C.; Anderson, J. M.; Cantley, L. C. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997, 275, 73-77.
16. Wiedemann, U.; Boisguerin, P.; Leben, R.; Leitner, D.; Krause, G.; Moelling, K.; Volkmer-Engert, R.; Oschkinat, H. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides. J. Mol. Biol. 2004, 343, 703-718.
17. Stiffter, M. A.; Chen, J. R.; Grantcharova, V. P.; Lei, Y.; Fuchs, D.; Allen, J. E.; Zaslavskaia, L. A.; MacBeath, G. PDZ domain binding selectivity is optimized across the mouse proteome. Science 2007, 317, 364-369.
18. Lim, I. A.; Hall, D. D.; Hell, J. W. Selectivity and promiscuity of the first and second PDZ domains of PSD-95 and synapse-associated protein 102. J. Biol. Chem. 2002, 277, 21697-21711.
19. Hung, A. Y.; Sheng, M. PDZ domains: structural modules for protein complex assembly. J. Biol. Chem. 2002, 277, 5699-5702.
20. Doyle, D. A.; Lee, A.; Lewis, J.; Kim, E.; Sheng, M.; MacKinnon, R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 1996, 85, 1067-1076.
21. Remaut, H.; Waksman, G. Protein-protein interaction through β-strand addition. Trends Biochem. Sci. 2006, 31, 436-444.
22. Chi, C. N.; Engström, A.; Gianni, S.; Larsson, M.; Jemth, P. Two conserved residues govern the salt and pH dependencies of the binding reaction of a PDZ domain. J. Biol. Chem. 2006, 281, 36811-36818.
23. Niethammer, M.; Kim, E.; Sheng, M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J. Neurosci. 1996, 16, 2157-2163.
24. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7-61.
25. Gardoni, F.; Di Luca, M. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol. 2006, 545, 2-10.
26. Hoyte, L.; Barber, P. A.; Buchan, A. M.; Hill, M. D. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol Med. 2004, 4, 131-136.
27. Brenman, J. E.; Chao, D. S.; Gee, S. H.; McGee, A. W.; Craven, S. E.; Santillano, D. R.; Wu, Z.; Huang, F.; Xia, H.; Peters, M. F.; Froehner, S. C.; Bredt, D. S. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and α1-syntrophin mediated by PDZ domains. Cell 1996, 84, 757-767.
28. Christopherson, K. S.; Hillier, B. J.; Lim, W. A.; Bredt, D. S. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 1999, 274, 27467-27473.
29. Aarts, M.; Liu, Y.; Liu, L.; Besshoh, S.; Arundine, M.; Gurd, J. W.; Wang, Y. T.; Salter, M. W.; Tymianski, M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002, 298, 846-850.
30. Aarts, M. M.; Tymianski, M. Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. Biochem. Pharmacol. 2003, 66, 877-886.
31. Cui, H.; Hayashi, A.; Sun, H. S.; Belmares, M. P.; Cobey, C.; Phan, T.; Schweizer, J.; Salter, M. W.; Wang, Y. T.; Tasker, R. A.; Garman, D.; Rabinowitz, J.; Lu, P. S.; Tymianski, M. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J. Neurosci. 2007, 27, 9901-9915.
32. Thomson Current Drugs; http://www.thomson.com.
33. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 48, 2518-2525.
34. Wen, W.; Wang, W.; Zhang, M. Targeting PDZ domain proteins for treating NMDA receptor-mediated excitotoxicity. Curr. Top. Med. Chem. 2006, 6, 711721.
35. Joshi, M.; Vargas, C.; Boisguerin, P.; Diehl, A.; Krause, G.; Schmieder, P.; Moelling, K.; Hagen, V.; Schade, M.; Oschkinat, H. Discovery of low-molecular-weight ligands for the AF6 PDZ domain. Angew. Chem., Int. Ed. 2006, 45, 3790-3795.
36. Hammond, M. C.; Harris, B. Z.; Lim, W. A.; Bartlett, P. A. β-Strand peptidomimetics as potent PDZ domain ligands. Chem. Biol. 2006, 13, 1247-1251.
37. Fujii, N.; Haresco, J. J.; Novak, K. A.; Stokoe, D.; Kuntz, I. D.; Guy, R. K. A selective irreversible inhibitor targeting a PDZ protein interaction domain. J. Am. Chem. Soc. 2003, 125, 12074-12075.
38. Fujii, N.; Haresco, J. J.; Novak, K. A.; Gage, R. M.; Pedemonte, N.; Stokoe, D.; Kuntz, I. D.; Guy, R. K. Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorg. Med. Chem. Lett. 2007, 17, 549-552.
39. Mayasundari, A.; Ferreira, A. M.; He, L.; Mahindroo, N.; Bashford, D.; Fujii, N. Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. Bioorg. Med. Chem. Lett. 2008, 18, 942-945.
40. Piserchio, A.; Salinas, G. D.; Li, T.; Marshall, J.; Spalier, M. R.; Mierke, D. F. Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem. Biol. 2004, 11, 469-173.
41. Fry, D. C.; Vassilev, L. T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med. 2005, 83, 955-963.
42. Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 2004, 332, 261-273.
43. Chi, C. N.; Gianni, S.; Calosci, N.; Travaglini-Allocatelli, C.; Engström, Å.; Jemth, P. A conserved folding mechanism for PDZ domains. FEBS Lett. 2007, 581, 1109-1113.
44. Gianni, S.; Engström, Å.; Larsson, M.; Calosci, N.; Malatesta, F.; Eklund, L.; Ngang, C. C.; Travaglini-Allocatelli, C.; Jemth, P. The kinetics of PDZ domain-ligand interactions and implications for the binding mechanism. J. Biol. Chem. 2005, 280, 34805-34812.
45. Saro, D.; Li, T.; Rupasinghe, C.; Paredes, A.; Caspers, N.; Spaller, M. R. A thermodynamic ligand binding study of the third PDZ domain (PDZ3) from the mammalian neuronal protein PSD-95. Biochemistry 2007, 46, 6340-6352.
46. Harris, B. Z.; Lau, F. W.; Fujii, N.; Guy, R. K.; Lim, W. A. Role of electrostatic interactions in PDZ domain ligand recognition. Biochemistry 2003, 42, 2797-2805.
47. Niethammer, M.; Valtschanoff, J. G.; Kapoor, T. M.; Allison, D. W.; Weinberg, R. J.; Craig, A. M.; Sheng, M. CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90. Neuron 1998, 20, 693-707.
48. Hruby, V. J. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discovery 2002, 1, 847-858.
49. + exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 2001, 276, 19683-19686.
50. Fukuyama, T.; Jow, C.-K.; Mui, C. 2- and 4-Nitrobenzenesulfonamides: exceptionally versatile means for preparation of secondary amines and protection of amines. Tetrahedron Lett. 1995, 36, 6373-6374.
51. Yang, L.; Chiu, K. Solid phase synthesis of Fmoc N-methyl amino acids: application of the Fukuyama amine synthesis. Tetrahedron Lett. 1997, 38, 7307-7310.
52. DeLano, W. L. The PyMOL Molecular Graphics System on World Wide Web; http://www.pymol.org.